SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), announced that Nanoviricides CEO Dr Anil Diwan joined ...
Overall, tailoring an HIV treatment regimen to individuals’ clinical and social context can help mitigate the persistent barriers to care access. Switching treatment is not just a clinical decision ...
For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...
Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
WEST PALM BEACH, FL – October 21, 2025 – PRESSADVANTAGE – All In Solutions Wellness Center, a Joint Commission-accredited ...
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...
The FDA has approved a new single-injection, once-monthly maintenance regimen for Eli Lilly’s Omvoh (mirikizumab-mrkz), ...
TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated ...
D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents – manufactured to the highest quality standards for faster, more efficient API development. TEWKSBURY, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback